Show simple item record

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

dc.contributor.authorBartlett, JMSen_US
dc.contributor.authorAhmed, Ien_US
dc.contributor.authorRegan, MMen_US
dc.contributor.authorSestak, Ien_US
dc.contributor.authorMallon, EAen_US
dc.contributor.authorDell'Orto, Pen_US
dc.contributor.authorThurlimann, Ben_US
dc.contributor.authorSeynaeve, Cen_US
dc.contributor.authorPutter, Hen_US
dc.contributor.authorVan de Velde, CJHen_US
dc.contributor.authorBrookes, CLen_US
dc.contributor.authorForbes, JFen_US
dc.contributor.authorViale, Gen_US
dc.contributor.authorCuzick, Jen_US
dc.contributor.authorDowsett, Men_US
dc.contributor.authorRea, DWen_US
dc.contributor.authorInhibitor, TAen_US
dc.date.accessioned2017-05-15T08:45:32Z
dc.date.available2017-04-03en_US
dc.date.issued2017-07en_US
dc.date.submitted2017-04-04T10:55:26.875Z
dc.identifier.issn0959-8049en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/23086
dc.description.sponsorshipThe BIG 1-98 trial was financed by Novartis and coordinated by the IBCSG [clinicaltrials.gov IDs = NCT00004205], including the design of the trial, data management, medical review, pathology review, and statistical support. The ATAC Trial was funded by AstraZeneca [clinicaltrials.gov IDs = NCT00849030] and Cancer Research UK. The TEAM trial was funded by Pharmacia/Pfizer [clinicaltrials.gov IDs = NCT00279448] and aspects of the biomarker work was funded by Cancer Research UK. John Bartlett was supported by funding from OICR which is provided through the Ontario Ministry of Research, Innovation and Science.en_US
dc.format.extent129 - 138en_US
dc.language.isoenen_US
dc.relation.ispartofEUROPEAN JOURNAL OF CANCERen_US
dc.rights© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectBreast canceren_US
dc.subjectHER2en_US
dc.subjectPredictionen_US
dc.subjectAromatase inhibitoren_US
dc.subjectMeta-analysisen_US
dc.titleHER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2en_US
dc.typeArticle
dc.rights.holder© 2017 Elsevier Ltd
dc.identifier.doi10.1016/j.ejca.2017.03.033en_US
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000402872000014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume79en_US


Files in this item

Thumbnail
Name:
Cuzick HER2 status predicts for ...
Size:
290.3Kb
Format:
application/
Description:
Accepted version
View/Open

This item appears in the following Collection(s)

Show simple item record